Setmelanotide in Pediatric Participants With Rare Genetic Diseases of Obesity
Study sponsor: Rhythm Pharmaceuticals, Inc. · RYTM
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2023-09-18Actual
Enrollment · participants12Actual
Source updated2024-11-27Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.